1
|
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.
|
Am J Surg Pathol
|
2008
|
1.65
|
2
|
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2012
|
1.49
|
3
|
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
|
Mol Cancer Ther
|
2010
|
1.29
|
4
|
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
|
Int J Cancer
|
2011
|
1.08
|
5
|
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
|
Neuro Oncol
|
2010
|
1.04
|
6
|
Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.
|
Transl Oncol
|
2008
|
0.98
|
7
|
High CD133 expression levels in gastrointestinal stromal tumors.
|
Cytometry B Clin Cytom
|
2011
|
0.83
|
8
|
Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.
|
Genes Chromosomes Cancer
|
2011
|
0.82
|
9
|
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?
|
Transl Oncol
|
2008
|
0.82
|
10
|
In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
|
Lab Invest
|
2013
|
0.79
|
11
|
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
|
Neuro Oncol
|
2014
|
0.78
|
12
|
A sporadic multiple GIST with unusual pathologic, molecular, and genetic features.
|
Am J Surg Pathol
|
2008
|
0.77
|
13
|
Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.
|
Anal Quant Cytol Histol
|
2010
|
0.75
|